Literature DB >> 19139983

Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments.

Ravit Arav-Boger1.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139983     DOI： 10.1007/s11262-008-0325-y

Source DB:  PubMed          Journal:  Virus Genes        ISSN： 0920-8569            Impact factor:   2.332


  70 in total

1.  Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.

Authors:  Bruce J Dezube; Susan E Krown; Jeannette Y Lee; Kenneth S Bauer; David M Aboulafia
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

Review 2.  Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.

Authors:  Robert Yarchoan; James M Pluda; Kathleen M Wyvill; Karen Aleman; Isaac R Rodriguez-Chavez; Giovanna Tosato; Andrew T Catanzaro; Seth M Steinberg; Richard F Little
Journal:  Crit Rev Immunol       Date:  2007       Impact factor: 2.214

3.  Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.

Authors:  Ariela Noy; David T Scadden; Jeannette Lee; Bruce J Dezube; David Aboulafia; Anil Tulpule; Sharon Walmsley; Parkash Gill
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

Review 4.  Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma.

Authors:  Carmen Manuela Klass; Margaret K Offermann
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

5.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  Akrit Sodhi; Risa Chaisuparat; Jiadi Hu; Amanda K Ramsdell; Brendan D Manning; Edward A Sausville; Earl T Sawai; Alfredo Molinolo; J Silvio Gutkind; Silvia Montaner
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

Review 7.  The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma.

Authors:  C Casper; A Wald
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

8.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.

Authors:  Sang-Hoon Sin; Debasmita Roy; Ling Wang; Michelle R Staudt; Farnaz D Fakhari; Dhavalkumar D Patel; David Henry; William J Harrington; Blossom A Damania; Dirk P Dittmer
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

9.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells.

Authors:  D Blankaert; T Simonart; J P Van Vooren; D Parent; C Liesnard; C M Farber; T Marique; J Werenne
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-07-01
View more
  4 in total

Review 1.  Human Gammaherpesvirus 8 Oncogenes Associated with Kaposi's Sarcoma.

Authors:  Amanda de Oliveira Lopes; Pedro do Nascimento Marinho; Letícia d'Ambrosio de Souza Medeiros; Vanessa Salete de Paula
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.

Authors:  Jayashree A Chandrasekharan; Xiao M Huang; Alexander C Hwang; Neelam Sharma-Walia
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

3.  Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation.

Authors:  Janet L Douglas; Jean K Gustin; Ashlee V Moses; Bruce J Dezube; Liron Pantanowitz
Journal:  Transl Biomed       Date:  2010

Review 4.  Lipoxins: nature's way to resolve inflammation.

Authors:  Jayashree A Chandrasekharan; Neelam Sharma-Walia
Journal:  J Inflamm Res       Date:  2015-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.